Gene therapy pioneer bluebird bags a 'breakthrough' title for lead program

February 2, 2015 12:26 PM

2 0

Bluebird bio nabbed the FDA's breakthrough drug title for LentiGlobin BB305 as a new treatment for beta-thalassemia major, putting one of the industry's top experimental gene therapies back squarely in a promising spotlight.

Bluebird's ($BLUE) BTD win helps solidify its rep as one of the leading gene therapy developers in biotech. The biotech believes that the scientific roller coaster ride in gene therapy work is over and that its lead therapy for beta-thalassemia and sickle cell diseases will prove that you can safely...

Read more

To category page